Your partner in science for end-to-end CRDMO solutions
Fragment-based drug discovery refers to the discovery efforts by employing fragments as the starting points for a target of interest. Diverse fragments are experimentally determined to bind to the target of interest and are either expanded or grown or linked together to form potent larger compounds.
Our expertise in SPR and crystallography enables synergistic application of the two platforms in FBDD efforts. At Jubilant Biosys, SPR (Surface Plasmon Resonance) platform is routinely used for fragment screening and the binding mode of the binding fragment is determined by X-Ray Crystallography.
